{"id":116505,"date":"2021-06-11T15:00:00","date_gmt":"2021-06-11T15:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2879835"},"modified":"2021-06-11T15:00:00","modified_gmt":"2021-06-11T15:00:00","slug":"the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others","status":"publish","type":"post","link":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/","title":{"rendered":"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others"},"content":{"rendered":"<p><img decoding=\"async\" width=\"200\" height=\"200\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Lag-3-Market-Insights.jpg?1623404913462\" alt=\"Lag-3-Market-Insights\" width=\"572\" height=\"326\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Market<\/strong><\/a><span style=\"font-weight: 400;\"> report also offers comprehensive insights into <\/span><strong>LAG-3-Next Generation Immunotherapy market size<\/strong><span style=\"font-weight: 400;\">, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing <\/span><strong>LAG-3-Next Generation Immunotherapy<\/strong><span style=\"font-weight: 400;\"> clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of <\/span><strong>LAG-3-Next Generation Immunotherapy<\/strong><span style=\"font-weight: 400;\"> market size forward in the 7MM [US, EU5(France, Germany, the United Kingdom, Spain, and Italy) and Japan].<\/span><\/p>\n<p><strong>Key facts of the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Market Report<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">According to Delveinsight, the market is anticipated to show positive growth due to the launch of upcoming therapies in the LAG-3 Next Generation<\/span> <span style=\"font-weight: 400;\">target during the forecast period 2022&ndash;2035. Moreover, the US will occupy the maximum market share in the overall market size in 2035.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">According to Delveinsight&#8217;s analysis, Among all LAG-3 target indications, <\/span><span style=\"font-weight: 400;\">NSCLC <\/span><span style=\"font-weight: 400;\">will occupy a significant market share of 98.81% by 2035.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The total LAG-3 Market Size by indications is expected to be USD 3,421 Million by 2035.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">According to Delveinsight&#8217;s analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022&ndash;2035).<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Currently, numerous trials are undergoing different indications for the LAG-3 target. Some of the major indications anticipated to show a better outcome by the launch of novel drugs include Breast Cancer, NSCLC, Gastric, Gastroesophageal Junction Cancer, Melanoma, Colorectal Cancer, Head and Neck Cancer, Multiple Myeloma.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The emerging trend in LAG3 Next-generation Immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies augurs the hopes for better therapeutic alternatives.<\/span><\/li>\n<\/ul>\n<p><strong>Request for Free Sample Report: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p><strong>Some of <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Companies<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">MacroGenics<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Novartis<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Bristol-Myers Squibb<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Merck<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Immutep<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Regeneron<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Xencor<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Incyte Biosciences<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Agenus<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">F-star Therapeutics<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">And Many Others<\/span><\/li>\n<\/ul>\n<p><strong>Cancer immunotherapy<\/strong><span style=\"font-weight: 400;\"> and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints, especially programmed death 1 (PD-1)\/programmed death-ligand 1 (PD-L1), has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint Lymphocyte Activation Gene-3 (LAG-3) holds considerable potential.<\/span><\/p>\n<p><strong>LAG-3<\/strong><span style=\"font-weight: 400;\"> suppresses T-cells activation and cytokine secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses. Targeting LAG-3 immunotherapy is moving forward in active clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance.<\/span><\/p>\n<p><strong>Request for Free Sample Report: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p><strong>Some of <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Drugs<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">MGD013<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">LAG525<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Relatlimab<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">MK-4280<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Eftilagimod Alpha<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">INCAGN2385<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">FS118<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">REGN3767<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">XmAb22841<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">And Many Others<\/span><\/li>\n<\/ul>\n<p><strong>Request for Free Sample Report: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p><strong>Scope of the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Market<\/strong><\/a><strong> Insight Report&nbsp;<\/strong><\/p>\n<ul>\n<li><strong>Geography Covered:<\/strong><span style=\"font-weight: 400;\"> The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/li>\n<li><strong>Study Period:<\/strong><span style=\"font-weight: 400;\"> 3-year historical and 10-year forecasted analysis (2020-2035).<\/span><\/li>\n<li><strong>Key LAG-3-Next Generation Immunotherapy Companies:<\/strong><span style=\"font-weight: 400;\"> MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, Regeneron, Xencor, and others.<\/span><\/li>\n<li><strong>Case Studies<\/strong><\/li>\n<li><strong>KOL&#8217;s Views<\/strong><\/li>\n<li><strong>Analyst&#8217;s View<\/strong><\/li>\n<\/ul>\n<p><strong>Learn more about the report offerings @<\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/onychomycosis-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong> LAG-3-Next Generation Immunotherapy Market Outlook<\/strong><\/a><\/p>\n<p><strong>Latest Blogs:<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/key-facts-to-know-about-triple-negative-breast-cancer-tnbc\/\"><span style=\"font-weight: 400;\">Facts To Know About TNBC In The Breast Cancer Awareness Month<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/breast-cancer-myths\/\"><span style=\"font-weight: 400;\">7 Most Common Myths: About Breast Cancer<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-market\/\"><span style=\"font-weight: 400;\">Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/breast-cancer-symptoms-causes-treatment\/\"><strong>Breast Cancer:<\/strong><span style=\"font-weight: 400;\"> Understand your breasts, recognize the symptoms<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Related Market Reports<\/strong><span style=\"font-weight: 400;\">:<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-negative-breast-cancer-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Her2 Negative Breast Cancer Market<\/strong><\/a><strong> Insight<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;<\/span><strong>Her2 Negative Breast Cancer Market <\/strong><span style=\"font-weight: 400;\">Insights, Epidemiology and Market Forecast 2030&#8243; report will provide deep insight into Her2 Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as <\/span><strong>Eisai, Genetech, G1 Therapeutics, Roche, Sanofi, AstraZeneca, and others.<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Her2 Positive Breast Cancer Market<\/strong><\/a><strong> Insight<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8216;Her2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030&#8217; report will provide deep insight into Her2 Positive Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as <\/span><strong>Roche, Puma Biotechnology, Seattle Genetics, MacroGenics, Prestige Biopharma, EirGenix, Roche, Genentech, Pfizer, Merck, Eli Lilly, Horizon Pharma, Kadcyla, Genentech, Novartis, and several others.<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-triple-negative-breast-cancer-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Metastatic Triple-Negative Breast Cancer Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Metastatic Triple-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030&#8221; report will provide deep insight into Metastatic Triple-Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as <\/span><strong>Immunomedics, Merck, Pfizer, Astellas, Roche, Tesaro, AstraZeneca, Cytodyn and several others.<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-Small Cell Lung Cancer Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Non-Small Cell Lung Cancer<\/span> <span style=\"font-weight: 400;\">Market Insights, Epidemiology, and Market Forecast- 2030&#8243; report will provide Non-Small Cell Lung Cancer<\/span> <span style=\"font-weight: 400;\">Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as <\/span><strong>Novartis Pharmaceuticals, AbbVie, Xcovery, Janssen Pharmaceuticals, Merck and several others.<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Multiple Myeloma Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Multiple Myeloma<\/span> <span style=\"font-weight: 400;\">Market Insights, Epidemiology, and Market Forecast-2030&#8243; report will provide Multiple Myeloma Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as <\/span><strong>AbbVie, Roche, Adaptimmune Therapeutics, GlaxoSmithKline, Merck Sharp &amp; Dohme Corp, Amgen, AstraZeneca, and others.<\/strong><\/p>\n<p><strong>Some of Newly Launched Report:&nbsp;<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/intracranial-pressure-monitoring-devices-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Intracranial Pressure Monitoring Devices Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/foot-and-ankle-devices-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Foot and Ankle Devices Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/electrophysiology-devices-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Electrophysiology Devices Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/growth-hormone-deficiency-ghd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Growth Hormone Deficiency Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/interventional-neuroradiology-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Interventional Neuroradiology Market<\/strong><\/a><strong> Insight<\/strong><\/li>\n<\/ul>\n<p><strong>About Delveinsight :&nbsp;<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight Business Research is a leading Market Research and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform <\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=gnw&amp;utm_medium=pr&amp;utm_campaign=vpr\"><strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Connect With Us at:<\/strong><strong>&nbsp;<\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"><strong>LinkedIn<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"> <strong>Facebook<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"> <strong>Twitter<\/strong><\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/lag-3-market\/\" rel=\"tag\">LAG-3 Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/nsclc-market\/\" rel=\"tag\">NSCLC Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/lag-3-next-generation-immunotherapy-market\/\" rel=\"tag\">LAG-3-Next Generation Immunotherapy Market<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Ankit Nigam info@delveinsight.com +91-9650213330<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Ankit Nigam<br \/> info@delveinsight.com<br \/> +91-9650213330<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\">The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\">The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-116505","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, [&hellip;] The post The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-11T15:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\",\"name\":\"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg\",\"datePublished\":\"2021-06-11T15:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"http:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/","og_locale":"en_US","og_type":"article","og_title":"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business","og_description":"DelveInsight&rsquo;s LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, [&hellip;] The post The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/","og_site_name":"Business","article_published_time":"2021-06-11T15:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/","url":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/","name":"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg","datePublished":"2021-06-11T15:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/06\/5353-Delveinsight20Logo.jpg"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/06\/11\/the-lag-3-next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight-macrogenics-novartis-bristol-myers-squibb-merck-immutep-and-others\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"http:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/116505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=116505"}],"version-history":[{"count":1,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/116505\/revisions"}],"predecessor-version":[{"id":116506,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/116505\/revisions\/116506"}],"wp:attachment":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=116505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=116505"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=116505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}